Xenon Pharmaceuticals stock trades at EUR 32.30 after trial pause

Published on 09/29/2026 at 15:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xenon Pharmaceuticals stock faces a USD 90.00 target after Jefferies cut it from USD 100.00 on September 28, 2026. Its NDA covers focal seizures.

XENE, CA98420N1050, Illustration mit AI erstellt.

Xenon Pharmaceuticals stock (ISIN CA98420N1050) was trading at EUR 32.30 at Lang & Schwarz on September 29, 2026, up 0.31 percent versus the prior close of EUR 32.20. The central issue is azetukalner, whose epilepsy opportunity is advancing while its psychiatry development carries a new trial risk.

Analysts cut targets after pause

Jefferies lowered its price target to USD 90.00 from USD 100.00 on September 28, 2026, while keeping a Buy rating, according to Investing.com. The same report said Deutsche Bank reduced its target to USD 46.00 from USD 90.00 and moved its rating from Buy to Hold.

The revisions followed Xenon's voluntary pause of new enrollment in Phase 3 studies for major depressive disorder and bipolar depression. The pause followed an analysis of neuropsychiatric adverse events, while patients already enrolled remained active, according to Xenon Pharmaceuticals in its release dated September 17, 2026.

Epilepsy program keeps moving

The same September 17 release said Xenon submitted an NDA for azetukalner in focal seizures to the FDA, supported by data from the Phase 2b X-TOLE study and Phase 3 X-TOLE2 study. The company said the two studies generated more than 1,500 patient-years of epilepsy safety and exposure data.

X-TOLE3 and X-ACKT continue to enroll patients, creating a separate development path from the paused psychiatry studies. Xenon also expects topline data from the X-NOVA2 major depressive disorder study in Q1 2027 after enrollment reached approximately 80 percent of its initial target of 450 patients, according to the company release.

Stock remains below its yearly high

Finance data placed the Nasdaq quote at USD 36.72 at 4:00 p.m. EDT on September 28, 2026, with a 52-week range of USD 36.07 to USD 72.66 and market capitalization of USD 3.5 billion. The euro quotation therefore sits against a company whose U.S. listing remains close to its yearly low in the latest primary-market snapshot.

For investors, the valuation debate now depends on whether the focal-seizure filing can offset uncertainty around psychiatric expansion. The price-target gap shows the split clearly: Jefferies retained a bullish rating at USD 90.00, while Deutsche Bank assigned a USD 46.00 target after its downgrade.

Lang and Schwarz price holds steady

Xenon Pharmaceuticals stock was trading at EUR 32.30 at Lang & Schwarz on September 29, 2026, at 2:42 p.m. CEST, up 0.31 percent versus the prior close of EUR 32.20 on September 28, 2026. The modest daily move leaves the clinical updates and the upcoming Q1 2027 data checkpoint as the key quantified reference points.